Introduction {#s1}
============

Gliomas are the most frequent primary brain tumors, currently managed through surgical resection, radiotherapy, and chemotherapy ([@B1]) approaches, but leading inevitably to large disability and mortality outcomes. The selection of the recommended therapeutic intervention in each case relies in estimates overall survival (OS) based commonly in histopathological and genetic criteria. However, current assessments of OS entail considerable uncertainties, limiting concomitantly more precise, effective, and personalized therapies. On these grounds, exploring additional criteria to improve OS predictions acquires vital relevance to improve treatment outcomes in glioma patients.

Histopathological and immunohistochemical criteria have classically provided the basis for the initial WHO classification of gliomas in grades I-IV ([@B2], [@B3]) determining, in general terms, the OS estimate and the recommended therapeutic intervention. More recently, the 2016 WHO classification of central nervous system tumors added an important collection of molecular signatures, restructuring the original histopathological classification of gliomas to include subgroups with specific genetic profiles ([@B4]). Although these refinements considerably improved the precision in the treatment prescribed, as well as our knowledge of glioma physiopathology and classification, the limited reproducibility of histopathological evaluations lead, not unfrequently, to imprecise histopathological classification and unreliable OS predictions at the individual level ([@B5]--[@B7]).

Magnetic Resonance Imaging approaches have been currently used to assess OS of gliomas. Briefly, radiomic parameters including surface area ([@B8]), shape features ([@B9]), tumor, and necrosis volumes, necrosis-tumor ratio ([@B10]) have been used to evaluate OS. However, these studies became many times limited to short OS periods as they evaluated only glioblastoma multiforme cases.

The metabolomic profiles of gliomas are able to provide an additional source of information to improve OS predictions, evaluating the down-stream metabolic alterations of aberrant cellularity and gene expression ([@B11]). Magnetic Resonance Spectroscopy (MRS) has been shown to be well-endowed to provide the metabolic profile of gliomas both *in vivo* and *in vitro* ([@B12], [@B13]). Briefly, *in vivo* ^1^H MRS revealed non-invasively, important hallmarks of cancer, including alterations in pH homeostasis ([@B14]), energy related ([@B15]), and phospholipid metabolites ([@B16], [@B17]), an ensemble of valuable metabolic fingerprints to classify high grade (HGG) or low grade gliomas (LGG) ([@B16], [@B18]). Moreover, the metabolic profiles determined by ^1^H MRS *in vivo* reached considerable clinical prognostic relevance ([@B19]--[@B22]). Alternatively, complementary *in vitro* HR-^1^H MRS approaches have proved to be able to resolve a larger number of metabolites than *in vivo* ^1^H MRS, thus increasing the size of the metabolome investigated, the number of potential alterations detected, and their influence on the tumoral phenotype, at the expense of the more invasive *in vitro* methodology ([@B23], [@B24]). However, the predictive role of the metabolomic profiles obtained by HR-^1^H MRS in providing OS estimates, received considerably less attention.

On these grounds, we aimed here to provide a pilot study evaluating OS estimates derived from metabolomic biomarkers as detected by HR-^1^H MRS, using a retrospective database of human glioma biopsies.

Materials and Methods {#s2}
=====================

Glioma Patients and Tumor Biopsies
----------------------------------

This study was approved by the Ethics Committee of Clinical Research from the University Hospital La Paz (<http://www.madrid.org/cs/Satellite?language=es&pagename=HospitalLaPaz/Page/HPAZ_home>) and carried out following their recommendations. All subjects gave written informed consent in accordance with the Declaration of Helsinki. We retrospectively reviewed the database of the Neurosurgery Department of the University Hospital La Paz, selecting 66 consecutive patients with glioma (grades I-IV) who underwent neurosurgery during the period 1992--1998 ([Figure 1](#F1){ref-type="fig"}). Briefly, solid parts of glioma tumors were extracted from the brain without the use of bipolar coagulation and divided into two adjacent and similar portions, one of them used for HR-^1^H MRS analysis and the other for histopathological diagnosis, following available WHO criteria ([@B25]). Tumor characteristics were evaluated by two independent radiologists and classified according to size, localization, and eloquence ([@B26]). Patients lost in follow up (*n* = 10) and those undergoing surgery for recurrence (*n* = 7) were excluded from further analysis. Grade I gliomas (*n* = 3) were also excluded because of their well-known physiopathological differences with the other glioma grades ([@B27], [@B28]). We then recovered the individual demographic, clinical, histopathological and *in vitro* spectroscopic ^1^H NMR features and gathered the OS information on postsurgical outcomes of these patients, including relevant clinical symptoms, adjuvant therapies, and OS time. No missing data for the variables of interest were found in these patients.

![Overview of glioma patient selection and implemented approach.](fonc-09-00328-g0001){#F1}

Histopathological Criteria
--------------------------

Histopathological grading of the biopsies was provided by the Anatomopathology Department of the Hospital, following standard WHO criteria ([@B25]), and archived until used in this study.

HR-^1^H MRS
-----------

The ^1^H MRS biopsy was immediately frozen in liquid nitrogen (−169°C) in the operating room of the Hospital and stored at −82°C until transferred in a liquid nitrogen container to the Institute of Biomedical Research CSIC/UAM for further processing and NMR analysis. Briefly, biopsies were reduced to powder in a previously chilled (methanol/dry ice) mortar, extracted with 6% perchloric acid, neutralized with KOD, lyophilized and resuspended in D~2~O (99.9% D) for ^1^H MRS analysis ([@B12]). HR-^1^H MRS spectra of biopsy extracts were acquired at 8.4 Tesla (360.13 MHz, pH 7.2, 22°C) in a Bruker AM-360 spectrometer equipped with a commercial ^1^H selective probe using 5-mm tubes and 0.5 ml of tissue extract. Acquisition conditions were: 90° pulses, 16.9 s total cycle time and 16,384 data points acquired in the time domain during of 1.901 s. The intensity of the residual water resonance was further reduced using a 5 s presaturating pulse centered on the water frequency. Prior to Fourier transformation, the free induction decays were zero-filled up to 128 K and multiplied by an exponential function resulting in 0.5 Hz artificial line broadening in the transformed spectrum. Further spectral processing, including phase and baseline corrections were performed by the same operator. Chemical shifts were referred to the methyl signal of TSP (2,2′-3,3′ tetradeutero trimethyl-sylil propionate sodium salt) at 0 ppm as an internal reference.

The following metabolites (resonances used in quantification, number of protons originating the resonance, multiplicity) could be consistently identified in the high resolution proton spectrum ([@B29]): Valine (1.09 ppm, 3H, d), Lactate (1.35 ppm, 3H, d), Alanine (1.45 ppm, 3H, d), Acetate (1.93 ppm, 3H, s), N-acetyl-aspartic acid (2.01 ppm, 3H, s), Gamma-amino butyric acid (2.31 ppm, 2H, t), Glutamate (2.43 ppm,2H, m), Glutamine (2.45 ppm, 2H, m), Aspartic acid (2.80 ppm, 2H, dd), Creatine (3.05 ppm, 3H, s) and Phosphocreatine (3.055 ppm, 3H, s), free Choline (3.20 ppm, 9H, s), Phosphorylcholine (3.22ppm, 9H, s), Glycerophophorylcholine (3.25 ppm, 9H, s), Taurine (3.45 ppm, 2H, t), Glycine (3.55 ppm, 2H, s), and Myo-inositol 4.07 ppm, 1H, dd). For every one of these metabolites, lorentzian curves were fitted to the most conveniently resolved proton resonances, and the resulting integral divided by the total number of protons of the corresponding metabolite ([@B6]). These values were further standardized by the sum of all the measured metabolites in the HR-^1^H NMR spectra and expressed as a molar percentage ([@B18], [@B30]). Assignments were performed with the aid of chemical shift values reported in the literature ([@B29], [@B31]) and confirmed when necessary by the addition of authentic standards.

Statistical Methods
-------------------

Statistical analyses were performed using the IBM SPSS Statistics 24 package as implemented on an Intel-PC platform, operating under Windows 10 environment. Univariate statistical approaches provided means and standard errors for the molar fractions of every metabolite. To investigate statistical dependences between clinical features and groups of OS, we used asymptotic chi-square with Monte Carlo exact probability tests, and to test the differences of means within each metabolic variable through the OS groups, we used the ANOVA test and Student *t*-tests. Finally, to explore the hierarchical contribution of individual HR-^1^H MRS biomarkers to the three groups of OS, we implemented a multivariate Classification Regression Tree (CRT) ([@B32]), classifying automatically the database using hierarchical nodes and branches, selecting step-wise the optimal discriminant biomarker for each split from the collection of available HR-^1^H MRS variables. The dependent variable was OS, using Chi-squared Automatic Interaction Detection (CHAID) as a growing method to provide automatically the optimal splits in every branch. Finally, we used these results to generate a Classification-Confusion Matrix (CCM), summarizing the correct and incorrect classifications provided by the metabolomics CRT, yielding the global percentage of correct classifications. Statistical significance in the ANOVA and multivariate analysis was defined as *p* = 0.05, considering confidence intervals higher than 95%.

Results {#s3}
=======

Glioma Database
---------------

We investigated 46 patients (23 males, 23 females) with a median age of 49 years, presenting the following glioma grade distribution; Grade II (11 cases), Grade III (16 cases), and Grade IV (19 cases). The database of glioma patients ([Figure 2](#F2){ref-type="fig"}) showed two clearly separated groups by OS, either depicting a Long Overall Survival (Long-OS) that survive more than 364 weeks (w), or less. The latter group, including patients with a wide range of survival (1--364 w), was further divided in two groups using the median of survival as a cut-point, resulting in Short Overall Survival (Short-OS) patients (1--52 w), or Intermediate Overall Survival (Intermediate-OS) patients (53--364 w), respectively.

![Histogram of OS in glioma patients after surgical resection at the Neurosurgery Department, University Hospital La Paz, in the period 1995--1998. Patient groups depicting Short-OS (1--52 w), Intermediate-OS (53--364 w) and Long-OS (\>364 w) are separated by the dotted lines.](fonc-09-00328-g0002){#F2}

Demographic, clinical, and radiological variables, therapeutic regimes and histopathological profiles of these groups are summarized in [Table 1](#T1){ref-type="table"}. A Chi-square Monte Carlo test was performed to compare the differences in independent clinical variables among the three survival categories. Radiotherapy, histopathologic grade, age, and localization showed statistically significant influence on OS.

###### 

Clinical features and overall survival of glioma patients.

  **Feature**                                            **Overall survival**   **Total patients *n* (% column)**   **Chi-square (montecarlo sig.)**                            
  ------------------------------------------------------ ---------------------- ----------------------------------- ---------------------------------- ----------- ------------ ---------
  Age                                                    \<25 y                 0 (0.0%)                            5 (62.5%)                          3(37.5%)    8 (17.4%)    0.01
                                                         25--54 y               5 (31.3%)                           7 (43.8%)                          4(25%)      16 (34.8%)   
                                                         \>54 y                 14 (63.6%)                          7 (31.8%)                          1 (4.5%)    22 (47.8%)   
  Sex                                                    Female                 8 (34.8%)                           11(47.8%)                          4 (17.4%)   23 (50%)     0.74
                                                         Men                    11(47.8%)                           8 (34.8%)                          4 (17.4%)   23 (50%)     
  Comorbility[^a^](#TN1){ref-type="table-fn"}            Yes                    10 (34.5%)                          13 (44.8%)                         6 (20.7%)   29 (63%)     0.56
                                                         No                     9 (52.9%)                           6 (35.3%)                          2 (11.8%)   17 (37%)     
  Localization[^b^](#TN2){ref-type="table-fn"}           A                      2 (15.4%)                           7 (53.8%)                          4 (30.8%)   13 (30.2%)   0.04
                                                         B                      5 (41.7%)                           6 (50%)                            1 (8.3%)    12 (27.9%)   
                                                         C                      12 (66.7%)                          3 (16.7%)                          3 (16.7%)   18 (41.9%)   
  Tumor volume[^b^](#TN2){ref-type="table-fn"}           Small                  13 (39.4%)                          15 (45.5%)                         5 (15.2%)   33 (73.3%)   0.49
                                                         Big                    6 (50%)                             3 (25%)                            3 (25%)     12 (26.7%)   
  Eloquency[^b^](#TN2){ref-type="table-fn"}              Yes                    16 (53.3%)                          10 (33.3%)                         4 (13.3%)   30 (69.8%)   0.19
                                                         No                     3 (23.1%)                           6 (46.2%)                          4(30.8 %)   13 (30.2%)   
  Resection                                              Partial/Complete       10 (52.6%)                          5 (26.3%)                          4 (21.1%)   19 (41.3%)   0.27
                                                         Biopsy                 9 (33.3%)                           14 (51.9%)                         4 (14.8%)   27 (58.7%)   
  Radiotherapy                                           Yes                    19 (54.3%)                          12 (34.3%)                         4 (11.4%)   35 (76.1%)   0.003
                                                         No                     0 (0%)                              7 (63.6%)                          4 (36.4%)   11 (23.9%)   
  Chemotherapy                                           Yes                    0 (0%)                              1 (33.3%)                          2 (66.7%)   3 (6.5%)     0.07
                                                         No                     19(44.2%)                           18 (41.9%)                         6 (14%)     43 (93.5%)   
  Histopathology grade[^c^](#TN3){ref-type="table-fn"}   II                     0 (0%)                              6 (54.5%)                          5 (45.5%)   11 (23.9%)   \<0.001
                                                         III                    3 (18.8%)                           10 (62.5%)                         3 (18.8%)   16 (34.8%)   
                                                         IV                     16(84.2%)                           3 (15.8%)                          0 (0%)      19 (41.3%)   

*Arterial hypertension, diabetes mellitus and/or pulmonary, renal, cardiac, oncologic or any severe disease*,

*Classification of tumors according to ([@B26])*.

*Histopathologic grade according to ([@B3])*.

HR-^1^H MRS
-----------

An illustrative example of underdetermined histopathological OS prediction is provided in [Figure 3](#F3){ref-type="fig"}, showing representative HR-^1^H MRS spectra from extracts of glioma biopsies obtained from two young male patients, assigned the same histopathological Grade II, but resulting in very different OS. Despite both patients underwent complete surgical resection without adjuvant radio- or chemotherapy, the patient represented in [Figure 3A](#F3){ref-type="fig"}, survived \<3 years (149 w), while the patient represented by [Figure 3B](#F3){ref-type="fig"} survived more than 11 years (605 w).

![Representative HR-^1^H MRS (360.13 MHz, 22°C, pH 7.2) from extracts of two glioma grade II biopsies with very different OS outcomes. **(A)** 149 w. **(B)** 600 w. MI, myo-inositol; Gly, glycine; GPC, glycerolphosphorylcholine; PC, phosphorylcholine; Cr, creatine; PCr, phosphocreatine; Glu, glutamate; Gln, glutamie; NAA, N-acetyl-aspartic acid; Ala, alanine; Lac, lactate.](fonc-09-00328-g0003){#F3}

Interestingly, HR-^1^H MRS spectra of these biopsies disclosed remarkable differences, particularly the relative increases in myo-inositol (MI) and glycerol-phosphorylcholine (GPC) in [Figure 3B](#F3){ref-type="fig"}. These findings suggested that HR-^1^H MRS analysis of biopsy extracts could contribute additional OS criteria to those normally obtained from general histopathological classification, thus prompting further HR-^1^H MRS analyses of the database.

Univariate Statistics
---------------------

OS was well-reflected in the metabolic profiles obtained, with evident relationships between OS and specific metabolite changes ([Figure 4](#F4){ref-type="fig"}). [Table 2](#T2){ref-type="table"} provides a more detailed analysis of the relationship between OS and specific metabolite molar fractions, highlighting the discriminant power in OS of each metabolite (*F*-value) and its statistical significance (*p*-value) as derived from ANOVA tests.

![Box-plots of metabolite molar ratios in extracts from glioma biopsies with Short-OS (green), Intermediate-OS (blue) and Long-OS (red). In each box, the central mark (white line) indicates the median, and the bottom and top edges refer to the 25-th and 75-th percentiles, respectively. The upper and lower limits of the box extend to the most extreme data points not considered outliers.](fonc-09-00328-g0004){#F4}

###### 

General linear model analysis of OS in glioma patients as revealed by the metabolic profile determined by HR-^1^H MRS.

  **Metabolite**   **Short (*n* = 19)**   **Intermediate (*n* = 19)**   **Long (*n* = 8)**   **Total**          ***F*[^b^](#TN5){ref-type="table-fn"}**   ***p***
  ---------------- ---------------------- ----------------------------- -------------------- ------------------ ----------------------------------------- -------------
  **MI**           **9.03 ± 1.26**        **14.75 ± 2.14**              **25.72 ± 1.51**     **14.30 ± 1.36**   **15.10**                                 **\<0.001**
  **Ala**          **8.47 ± 1.12**        **5.67 ± 0.95**               **1.67 ± 0.24**      **6.13 ± 0.70**    **13.65**                                 **\<0.001**
  **GPC**          **3.17 ± 0.34**        **5.17 ± 0.72**               **7.18 ± 0.97**      **4.70 ± 0.42**    **9.44**                                  **\<0.001**
  **Gly**          **13.38 ± 1.89**       **6.95 ± 1.03**               **3.61 ± 0.68**      **9.03 ± 1.05**    **9.37**                                  **\<0.001**
  **PC**           **4.17 ± 0.48**        **2.84 ± 0.48**               **1.43 ± 0.28**      **3.14 ± 0.32**    **8.36**                                  **0.001**
  **tCr**          **13.36 ± 1.10**       **15.03 ± 1.19**              **20.84 ± 1.63**     **15.35 ± 0.81**   **6.53**                                  **0.003**
  **Ac**           **4.49 ± 0.97**        **3.09 ± 0.81**               **0.94 ± 0.17**      **3.30 ± 0.55**    **5.72**                                  **0.006**
  **fCho**         **1.33 ± 0.13**        **0.86 ± 0.17**               **0.73 ± 0.24**      **1.03 ± 0.10**    **4.65**                                  **0.01**
  **Glu**          **12.20 ± 1.27**       **12.09 ± 1.56**              **6.04 ± 1.16**      **11.08 ± 0.91**   **3.62**                                  **0.03**
  Gln              15.47 ± 1.19           18.76 ± 1.38                  18.51 ± 1.30         17.36 ± 0.81       2.02                                      0.14
  Val              2.34 ± 0.47            1.60± 0.43                    1.45 ± 0.23          1.88 ± 0.27        0.896                                     0.42
  Asp              0.77 ± 0.14            0.70 ± 0.14                   0.50 ± 0.12          0.69 ± 0.09        0.584                                     0.56
  NAA              3.35 ± 0.94            4.57 ± 0.95                   4.55 ± 0.94          4.06 ± 0.57        0.544                                     0.58
  GABA             1.25 ± 0.31            0.92 ± 0.15                   1.17 ± 0.33          1.10 ± 0.15        0.483                                     0.62
  Tau              5.69 ± 0.79            6.17 ± 0.71                   4.95 ± 0.63          5.76 ± 0.45        0.416                                     0.66
  tCho             8.67 ± 0.57            8.88 ± 0.76                   9.33 ± 1.02          8.87 ± 0.42        0.145                                     0.86

*Results are given as mean ± standard error of mean*.

*A Box Cox transform was performed on the data before running ANOVA analysis. Ac, Acetate; Ala, Alanine; Asp, aspartic acid; fCho, free choline; GABA, gamma-aminobutyric acid; Gln, glutamine; Glu, glutamate; Gly, glycine; GPC, glycerophosphocholine; MI, myo-inositol; NAA, N-acetyl-aspartic acid; PC, phosphorylcholine; Tau, taurine; tCr, total creatine; Val, valine. Bold characters indicate p \< 0.05*.

Briefly, OS increased with increasing levels of MI, GPC, and total Creatine (tCr), and decreased with increasing levels of alanine (Ala), free choline (fCho), glutamate (Glu), phosphorylcholine (PC), and glycine (Gly). The remaining metabolites detected by HR-^1^H NMR, including acetate (Ac), glutamine (Gln), valine (Val), aspartate (Asp), N-acetyl-aspartic acid (NAA), Gamma-amino butyric (GABA), taurine (Tau), and total choline (tCho) were not found to influence significantly OS. The most powerful discriminators of OS were (Metabolite/ F value/ *p*-value) in decreasing order; MI/15.1/0.000, Ala/13.6/0.000, GPC/9.5/0.001, Gly/9.4/0.000, tCr/6.5/0.003, Ac/5.7/0.006, fCho/4.6/0.015, Glu/3.6/0.035.

We also investigated the relationship between histopathological grade and the molar fractions of metabolites detectable in extracts glioma biopsies using ANOVA tests ([Table 3](#T3){ref-type="table"}). Notably, the priority of metabolites providing optimal glioma grade discrimination, was different from the one yielding optimal OS discriminative power ([Table 2](#T2){ref-type="table"}). The following molar ratios of metabolites were found to provide optimal discriminant power between histopathological grades (metabolite/*F*-value/*p*-value); MI/21.7/0.000, PC/11.7/0.000, GPC/9.2/0.000, Ala/8.8/0.001, Gly/6.5/0.003, tCr/6.3/0.004, Glu 5.9/0.005 and Gln/3.5/0.040.

###### 

General linear model analysis of the HR- ^1^H NMR metabolic profiles associated to different glioma histopathological grades.

                                                                **IV**                                            **III**            **II**             **Total**          **F**                                       **p**
  ------------------------------------------------------------- ------------------------------------------------- ------------------ ------------------ ------------------ ------------------------------------------- -------------
  **HISTOPATHOLOGICAL GRADE[^a^](#TN6){ref-type="table-fn"}**                                                                                                                                                          
  **MI**                                                        **8.41 ± 1.09[^b^](#TN7){ref-type="table-fn"}**   **13.94 ± 1.95**   **24.99 ± 2.3**    **14.3 ± 1.36**    **21.71[^c^](#TN8){ref-type="table-fn"}**   **\<0.000**
  **PC**                                                        **4.36 ± 0.56**                                   **2.90 ± 0.36**    **1.40 ± 0.25**    **3.14 ± 0.32**    **11.74**                                   **\<0.000**
  **GPC**                                                       **3.01 ± 0.19**                                   **5.32 ± 0.84**    **6.70 ± 0.87**    **4.70 ± 0.42**    **9.16**                                    **\<0.000**
  **Ala**                                                       **8.36 ± 1.15**                                   **5.77 ± 1.09**    **2.82 ± 0.69**    **6.13 ± 0.7**     **8.85**                                    **0.001**
  **Gly**                                                       **12.74 ± 1.9**                                   **7.98 ± 1.42**    **4.14 ± 0.53**    **9.03 ± 1.05**    **6.54**                                    **0.003**
  **tCr**                                                       **13.54 ± 1.17**                                  **14.35 ± 1.31**   **19.94 ± 1.28**   **15.35 ± 0.81**   **6.30**                                    **0.004**
  **Glu**                                                       **13.85 ± 1.55**                                  **10.89 ± 1.32**   **6.59 ± 0.95**    **11.08 ± 0.91**   **5.90**                                    **0.005**
  **Succ**                                                      **1.36 ± 0.49**                                   **1.11 ± 0.2**     **0.58 ± 0.08**    **1.09 ± 0.22**    **3.99**                                    **0.03**
  **Gln**                                                       **14.95 ± 1.14**                                  **19.05 ± 1.31**   **19.05 ± 1.67**   **17.36 ± 0.81**   **3.47**                                    **0.04**
  fCho                                                          1.23 ± 0.13                                       1.05 ± 0.21        0.67 ± 0.16        1.03 ± 0.1         3.10                                        0.05
  Val                                                           2.32 ± 0.48                                       1.97 ± 0.49        0.98 ± 0.11        1.88 ± 0.27        2.51                                        0.09
  Asp                                                           0.88 ± 0.16                                       0.63 ± 0.12        0.47 ± 0.12        0.69 ± 0.09        1.93                                        0.16
  Ac                                                            3.75 ± 0.96                                       3.68 ± 0.98        1.95 ± 0.67        3.30 ± 0.55        1.49                                        0.24
  Tau                                                           6.09 ± 0.85                                       6.05 ± 0.74        4.77 ± 0.46        5.76 ± 0.45        0.42                                        0.66
  tCho                                                          8.60 ± 0.57                                       9.27 ± 0.86        8.76 ± 0.83        8.87 ± 0.42        0.24                                        0.79
  GABA                                                          1.03 ± 0.19                                       1.25 ± 0.36        1.02 ± 0.23        1.10 ± 0.15        0.23                                        0.80
  NAA                                                           4.14 ± 1.17                                       4.06 ± 0.86        3.94 ± 0.49        4.06 ± 0.57        0.01                                        0.99

According to Louis et al. ([@B3])

*Results are given as mean ± standard error of mean*.

*A Box Cox transform was performed on the data before running ANOVA analysis. Bold characters indicate p \< 0.05*.

Together, these results show that relevant metabolites contribute with different strengths either to histopathological grading or to OS predictions.

Classification Regression Trees (CRT)
-------------------------------------

To investigate the hierarchical contribution of these metabolites to the OS observed, we implemented a multivariate CRT ([Figure 5](#F5){ref-type="fig"}) ([@B32]). Starting with the complete patient database (Node 0), high MI levels (Branch 1) provided the most powerful biomarker to predict Long-OS survival within the three OS groups. MI levels ≤ 23.35 were found in 37 biopsies (Node 1). Of these, only one patient survived more than 7 years (Long-OS), while the rest of the patients depicted either Intermediate- (17 patients) or Short-OS (19 patients). In contrast, MI levels \>23.35 were detected in nine biopsies (Node 2), of which seven (77.8%) depicted Long-OS, two showed Intermediate-OS, and none had a Short-OS, suggesting that high MI levels dismiss a Short-OS prediction.

![Classification Regression Tree (CRT) of glioma OS based in metabolomic biomarkers detectable by HR-^1^H MRS.](fonc-09-00328-g0005){#F5}

Patients with MI levels ≤ 23.35 could be further split in two groups using GPC (Brach 2). Sixty-nine percent of the patients with GPC levels ≤ 4.36 (Node 3) were classified as Short-OS, while 91% of the patients with GPC \> 4.36 (Node 4) were classified as Intermediate-OS. GPC provided thus a convenient biomarker to distinguish between Short- and Intermediate-OS estimates.

The metabolomic CRT grew beyond Branch 2, improving the classification using either Gly or Ala splits (Branch 3). All patients of Node 3 with Gly levels higher 13.87 (Node 6), depicted Short-OS, suggesting that high Gly levels are predictive of a negative outcome. Patients from Node 4, could be further stratified by their Ala levels. Those having Ala levels lower than 8.48 (Node 7) indicated Intermediate-OS (100%). Summarizing, the metabolomic CRT indicated dominant roles of MI, GPC, Ala, and Gly OS prediction of glioma patients.

Finally, we compared the number of correct predictions derived from the metabolomic CRT with those observed clinically, in the Classification-Confusion Matrix of [Table 4](#T4){ref-type="table"}. Out of 19 patients in the Short-OS group, the metabolomic approach classified correctly 18 patients. In the Intermediate-OS group, the metabolomic approach classified correctly 15 of 19 patients. Finally, out of the 8 patients identified with Long-OS, the metabolomic approach correctly classified 6 patients.

###### 

Classification confusion matrix of correct/incorrect classifications of overall survival in patients bearing gliomas using metabolomic criteria.

  **Observed overall survival (*n* = 46)**   **Predicted overall survival**           **Percent correct classifications**           
  ------------------------------------------ ---------------------------------------- ------------------------------------- ------- ----------
  Short (*n* = 19)                           **18**[^a^](#TN9){ref-type="table-fn"}   1                                     0       **94.7**
  Intermediate (*n* = 19)                    4                                        **15**                                0       **78.9**
  Long (*n* = 8)                             1                                        1                                     **6**   **75.0**
  All patients (*n* = 46)                                                                                                           **84.7**

*Numbers in bold indicate number and percentages of correct classifications. Growing Methods: CRT, dependent variable OS*.

In summary, the metabolomic classification reached defined OS predictions in all three groups, separating well the longer OS groups (Intermediate-OS and Long-OS). This entails considerable relevance, since the prediction of Long-OS in glioma patients remains currently a vital challenge for neurosurgeons, with important implications in the definition of the recommended therapeutic strategy.

Discussion {#s4}
==========

Previous OS Studies
-------------------

The present study complements and extends earlier OS predictors based on the WHO classification ([@B2]--[@B4]) or *in vivo* MRI/MRS studies ([@B19]--[@B21], [@B33]--[@B40]), contributing a novel array of metabolomic biomarkers organized hierarchically by a multivariate CRT. Earlier studies implementing *in vivo* MRS/MRI approaches investigated mainly glioblastoma patients ([Table 5](#T5){ref-type="table"}), associating Short-OS to increases in PC ([@B4]) and tCho/NAA ([@B20], [@B36]--[@B40], [@B42]), and longer OS to higher contents in GPC ([@B35]). Additionally, Cho/Cr ratio has been proposed as a biomarker of cellular proliferation and prognosis ([@B22]). More recently, a correlation between 2-hydroxiglutarate and the IDH1 mutation ([@B43]), suggested that *in vivo* detection of 2-hydroxiglutarate could become a useful prognostic biomarker. However, routinely and regular detection *in vivo* of 2-hydroxyglutarate still remains an important technological challenge in most imaging centers, limiting wider applications. In summary, the present study contributes a larger cohort of patients examined by routinely available *in vitro* MRS, followed during a longer period of time, including also a collection of both Low Grade Gliomas (LGG) and High Grade Gliomas (HGG). Notably, some of the metabolomic biomarkers found valuable here in OS prediction, like MI or GPC ([Table 2](#T2){ref-type="table"}), are difficult to resolve, or not even detectable *in vivo*. Consequently, our results suggest that postsurgical HR-^1^H NMR analysis of extracted tumor biopsies may provide a useful complement to available *in vivo* MRS explorations when addressing OS predictions.

###### 

Overview of literature correlating OS and MRS biomarkers.

  **Authors & year**              **Patients**   **Glioma grade**                       **Follow-up period[^a^](#TN10){ref-type="table-fn"}, [^b^](#TN11){ref-type="table-fn"}**
  ------------------------------- -------------- -------------------------------------- ------------------------------------------------------------------------------------------
  Li et al. ([@B39])              72             HGG[^c^](#TN12){ref-type="table-fn"}   17.2 m[^a^](#TN10){ref-type="table-fn"}
  Reijneveld et al. ([@B40])      14             LGG[^d^](#TN13){ref-type="table-fn"}   30 m (9--40)[^b^](#TN11){ref-type="table-fn"}
  Hattingen et al. ([@B41])       45             LGG                                    37 m (52.1--260.5)
  Chang et al. ([@B38])           143            LGG & HGG                              n.s.
  Yamasaki et al. ([@B33])                       HGG                                    26.1 m (6.5--83.8)
  Steffen-Smith et al. ([@B37])   39             HGG                                    7.1 m (1.6--61.6)
  Quon et al. ([@B36])            26             HGG                                    22.9 m (5--37)
  Hattingen et al. ([@B35])       32             HGG (recidives)                        8.1 m
  Tolia et al. ([@B21])           12             HGG                                    n.s.
  Steidl et al. ([@B34])          37             HGG (recidives)                        n.s.
  Roldán et al. ([@B20])          28             HGG                                    3--98 m
  Present serie                   46             LGG & HGG                              14.9 m (0.24--170.4)

*Median of the duration of the study in months*,

*Parenthesis includes the range of the study in months (m)*,

*HGG: High grade glioma*,

*LGG: Low grade glioma, n.s.: not specified*.

Metabolomic CRT
---------------

We implemented a CRT methodology to find, hierarchically, the best classification of OS estimates, using metabolomic criteria. These results complement the earlier decision tree of Li et al. ([@B39]), who considered age, MRI features (T~2~, T~1~, Volume Contrast Enhancement) and *in vivo* spectroscopic biomarkers (Lip+Lac, Cho/Cr, and Cr/NAA), as the main determinants predicting glioblastoma OS.

Our metabolomic CRT grew up to three branches. In the first branch, MI became the most robust biomarker of survival, with larger MI contents revealing longer survivals. Increased MI levels have been reported in inflammatory diseases as Alzheimer ([@B41]), renal failure ([@B44]), diabetes mellitus ([@B44]), and traumatic brain injury ([@B45], [@B46]), suggesting a universal role of this osmolite in pathophysiolological volume regulation. However, MI levels were reported previously to increase ([@B47]--[@B49]) or decrease ([@B44]) with increasing glioma grade *in vivo*. Present results reveal that higher MI levels are associated to longer OS, and lower tumoral grades ([Table 3](#T3){ref-type="table"}). Since MI occurs primarily in normal astrocytes ([@B44]), we hypothesize that the MI resonances detected in the tumor biopsies reveal the healthy astrocyte content within the tumor mass. Larger relative MI contents reveal indirectly relatively larger normal astrocyte populations and smaller tumoral cell burdens, supporting consequently longer OS ([@B41], [@B50], [@B51]).

The second hierarchical branch classifying the lower MI content group, is GPC, with higher GPC levels predicting longer OS. We, and others, have previously reported that relatively higher contributions of GPC and PC are associated to low and high grade gliomas, respectively ([@B16], [@B52]). Interestingly, GPC and PC levels are thought to reflect the balance between phospholipid degradation and phospholipid synthesis, respectively, with increased GPC levels revealing relatively a negative balance between synthesis and degradation, lower tumoral proliferation, and more prolonged survivals.

Gly and Ala provided the third branch of OS discrimination for patient groups with low or high levels of GPC, respectively. High Gly and Ala levels revealed poor prognosis, associated to shorter OS. Indeed, Ala and Gly levels previously reported as hypoxia and redox stress biomarkers ([@B53]), revealing tumoral progression to hypoxia, redox stress, and fatal energy failure. They can now be associated to shorter OS predictions.

Limitations
-----------

The time span of biopsy collection in this study preceded some of the advances in the characterization of glioma genetics and their influence in malignancy and OS. This circumstance, and the long survival period investigated, precluded the use of genetic biomarkers validated later in the coverage of the present retrospective study. Thus, the correlations between metabolomic and genomic biomarkers of OS in glioma deserve further investigation. Finally, the number of patients involved in the present pilot study is admittedly small but sufficiently robust to support the use of metabolomic biomarkers detected by *in vitro* HR-^1^HMRS in OS predictions of postsurgical survival from glioma patients. A multicenter study to extend the number of patients and hospitals involved, is currently being implemented.

Conclusion {#s5}
==========

We used a multivariate CRT to assess postsurgical OS predictions based in the ^1^H HR-MRS analysis of the metabolomic profile from neurosurgical biopsies of glioma patients. Present results show that the metabolic profiles of glioma biopsies constitute accurate and independent biomarkers of OS in glioma patients.
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